BIKTARVY® Official HCP Website from Gilead | BIKTARVY® HCP
Find HCP info about BIKTARVY® (bictegravir, emtricitabine, tenofovir alafenamide). View full Prescribing Information, including BOXED WARNING.
BIKTARVY® Resistance Summary | Official HCP Site
See resistance data in clinical trials with BIKTARVY® (bictegravir, emtricitabine, tenofovir alafenamide). Read full Prescribing Info, including BOXED WARNING.
BIKTARVY® Cost Support | BIKTARVY® HCP
Find patient cost, co-pay & insurance support options for BIKTARVY® (bictegravir, emtricitabine, tenofovir alafenamide). Read full Prescribing Info, including BOXED WARNING.
BIKTARVY® Components, Mechanism of Action & Tenofovir …
BIKTARVY® is indicated as a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing ≥14 kg who have no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA . 50 copies per mL) on a stable ARV regimen with no known or suspected ...
Clinical Studies in Virologically Suppressed Adults - BIKTARVY® HCP
Gilead Sciences, Inc. 5. Kumar P, Stephens JL, Wurapa AK, et al. Week 72 outcomes and COVID-19 impact from the BRAAVE 2020 study: a randomized switch to B/F/TAF in Black American adults with HIV. Poster presented at: International AIDS Society Conference on HIV Science; July 18-21, 2021; Virtual.
Early Treatment Initiation With BIKTARVY® | Official HCP Site
Learn about early treatment initiation with BIKTARVY® (bictegravir, emtricitabine, tenofovir alafenamide). Read full Prescribing Info, including BOXED WARNING.
Dosing Information - BIKTARVY® HCP
Find information about dosing for BIKTARVY® (bictegravir, emtricitabine, tenofovir alafenamide). Read full Prescribing Information, including BOXED WARNING.
Adverse Reactions & Discontinuations | Official HCP Site
Studies 1489 and 1490: Proven long-term safety and tolerability profile through Week 240 in adults initially randomized to BIKTARVY or switched to BIKTARVY at Week 144 2,3,5. Study 1489. ARs (All Grades) Reported in ≥2% of Adults Who Received BIKTARVY.
Starting HIV Treatment Early - BIKTARVY® HCP
BIKTARVY® is indicated as a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing ≥14 kg who have no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA . 50 copies per mL) on a stable ARV regimen with no known or suspected ...
BIKTARVY® Clinical Trial Experience | Official HCP Site
See an overview of the BIKTARVY® (bictegravir, emtricitabine, tenofovir alafenamide) clinical trials. Read full Prescribing Info, including BOXED WARNING.